Talazoparib is an orally available small molecule inhibitor of the DNA repair enzyme poly ADP-ribose polymerase (PARP) that is used as an antineoplastic agent in the treatment of selected cases of breast cancer. Talazoparib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury. It is grouped under the following drug class(es): Antineoplastic agents and PARP Inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include (8S, 9R)-5-Fluoro-8-(4-fluorophenyl)-2, 7, 8, 9-tetrahydro-9-(1-methyl-1H-1, 2, 4-triazol-5-yl)-3H-pyrido[4, 3 and 2-de]phthalazin-3-one. Its PubChem CID is 135565082.
Talazoparib
| CAS No | 1207456-01-6 |
|---|---|
| Molecular Formula | C19H14F2N6O |
| Molecular Weight | 380.4 g/mol |
| Synonyms | (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Talazoparib is an orally available small molecule inhibitor of the DNA repair enzyme poly ADP-ribose polymerase (PARP) that is used as an antineoplastic agent in the treatment of selected cases of breast cancer.
The listed CAS number is 1207456-01-6.
The listed molecular formula is C19H14F2N6O.
The listed molecular weight is 380.4 g/mol.
(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one.
The source lists (8S, 9R)-5-Fluoro-8-(4-fluorophenyl)-2, 7, 8, 9-tetrahydro-9-(1-methyl-1H-1, 2, 4-triazol-5-yl)-3H-pyrido[4, 3 and 2-de]phthalazin-3-one.